The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Female Infertility Drugs Market Research Report 2025
Synopsis
Female infertility refers to infertility in women. It affects an estimated 48 million women,with the highest prevalence of infertility affecting people in South Asia, Sub-Saharan Africa, North Africa/Middle East, and Central/Eastern Europe and Central Asia.
The global Female Infertility Drugs market was valued at US$ 4636.8 million in 2023 and is anticipated to reach US$ 6842.7 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Female Infertility Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Female Infertility Drugs.
Report Scope
The Female Infertility Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Female Infertility Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Female Infertility Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan Plc
Ferring BV
Merck KGaA
Novartis AG
Sanofi
Segment by Type
Parenteral
Oral
Others
Segment by Application
Ovarian Hyperstimulation Syndrome
Multiple-gestation Pregnancies
Multiple-birth Infants
Premature Labor
Low Birth Weight
Risk of Cesarean Delivery
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Female Infertility Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Female infertility refers to infertility in women. It affects an estimated 48 million women,with the highest prevalence of infertility affecting people in South Asia, Sub-Saharan Africa, North Africa/Middle East, and Central/Eastern Europe and Central Asia.
The global Female Infertility Drugs market was valued at US$ 4636.8 million in 2023 and is anticipated to reach US$ 6842.7 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Female Infertility Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Female Infertility Drugs.
Report Scope
The Female Infertility Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Female Infertility Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Female Infertility Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan Plc
Ferring BV
Merck KGaA
Novartis AG
Sanofi
Segment by Type
Parenteral
Oral
Others
Segment by Application
Ovarian Hyperstimulation Syndrome
Multiple-gestation Pregnancies
Multiple-birth Infants
Premature Labor
Low Birth Weight
Risk of Cesarean Delivery
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Female Infertility Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Female Infertility Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Parenteral
1.2.3 Oral
1.2.4 Others
1.3 Market by Application
1.3.1 Global Female Infertility Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Ovarian Hyperstimulation Syndrome
1.3.3 Multiple-gestation Pregnancies
1.3.4 Multiple-birth Infants
1.3.5 Premature Labor
1.3.6 Low Birth Weight
1.3.7 Risk of Cesarean Delivery
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Female Infertility Drugs Market Perspective (2019-2030)
2.2 Female Infertility Drugs Growth Trends by Region
2.2.1 Global Female Infertility Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Female Infertility Drugs Historic Market Size by Region (2019-2024)
2.2.3 Female Infertility Drugs Forecasted Market Size by Region (2025-2030)
2.3 Female Infertility Drugs Market Dynamics
2.3.1 Female Infertility Drugs Industry Trends
2.3.2 Female Infertility Drugs Market Drivers
2.3.3 Female Infertility Drugs Market Challenges
2.3.4 Female Infertility Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Female Infertility Drugs Players by Revenue
3.1.1 Global Top Female Infertility Drugs Players by Revenue (2019-2024)
3.1.2 Global Female Infertility Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Female Infertility Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Female Infertility Drugs Revenue
3.4 Global Female Infertility Drugs Market Concentration Ratio
3.4.1 Global Female Infertility Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Female Infertility Drugs Revenue in 2023
3.5 Female Infertility Drugs Key Players Head office and Area Served
3.6 Key Players Female Infertility Drugs Product Solution and Service
3.7 Date of Enter into Female Infertility Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Female Infertility Drugs Breakdown Data by Type
4.1 Global Female Infertility Drugs Historic Market Size by Type (2019-2024)
4.2 Global Female Infertility Drugs Forecasted Market Size by Type (2025-2030)
5 Female Infertility Drugs Breakdown Data by Application
5.1 Global Female Infertility Drugs Historic Market Size by Application (2019-2024)
5.2 Global Female Infertility Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Female Infertility Drugs Market Size (2019-2030)
6.2 North America Female Infertility Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Female Infertility Drugs Market Size by Country (2019-2024)
6.4 North America Female Infertility Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Female Infertility Drugs Market Size (2019-2030)
7.2 Europe Female Infertility Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Female Infertility Drugs Market Size by Country (2019-2024)
7.4 Europe Female Infertility Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Female Infertility Drugs Market Size (2019-2030)
8.2 Asia-Pacific Female Infertility Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Female Infertility Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Female Infertility Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Female Infertility Drugs Market Size (2019-2030)
9.2 Latin America Female Infertility Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Female Infertility Drugs Market Size by Country (2019-2024)
9.4 Latin America Female Infertility Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Female Infertility Drugs Market Size (2019-2030)
10.2 Middle East & Africa Female Infertility Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Female Infertility Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Female Infertility Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan Plc
11.1.1 Allergan Plc Company Detail
11.1.2 Allergan Plc Business Overview
11.1.3 Allergan Plc Female Infertility Drugs Introduction
11.1.4 Allergan Plc Revenue in Female Infertility Drugs Business (2019-2024)
11.1.5 Allergan Plc Recent Development
11.2 Ferring BV
11.2.1 Ferring BV Company Detail
11.2.2 Ferring BV Business Overview
11.2.3 Ferring BV Female Infertility Drugs Introduction
11.2.4 Ferring BV Revenue in Female Infertility Drugs Business (2019-2024)
11.2.5 Ferring BV Recent Development
11.3 Merck KGaA
11.3.1 Merck KGaA Company Detail
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Female Infertility Drugs Introduction
11.3.4 Merck KGaA Revenue in Female Infertility Drugs Business (2019-2024)
11.3.5 Merck KGaA Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Female Infertility Drugs Introduction
11.4.4 Novartis AG Revenue in Female Infertility Drugs Business (2019-2024)
11.4.5 Novartis AG Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Female Infertility Drugs Introduction
11.5.4 Sanofi Revenue in Female Infertility Drugs Business (2019-2024)
11.5.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
